ArticleEye (London, England)2025
Prevalence and associated factors for retinopathy of prematurity at a tertiary hospital in Dar es Salaam, Tanzania.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and associated factors of retinopathy of prematurity in sub‑Saharan Africa: a systematic review and meta‑analysis.BMC ophthalmology · 2025Pooled it
- Risk factors for severe retinopathy of prematurity: A retrospective case-control study.Experimental and therapeutic medicine · 2026Article
- Variations in prevalence of retinopathy of prematurity (ROP) and completeness of screening in five units within a South African region: a register-based study.Eye (London, England) · 2026Observational
- Surviving Extremely Low Birth Weight Infants Have a Higher Risk of ROP in Sub-Saharan Africa.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Construction of a predictive model for retinopathy of prematurity using machine learning algorithms.BMC ophthalmology · 2025Article
- The aftermath of retinopathy of prematurity blindness.Eye (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinopathy of prematurity (ROP) is one of the leading causes of preventable childhood blindness worldwide. There has been a rapid increase in neonatal units in Tanzania leading to increased survival of preterm babies, which lead to increasing number of babies at risk of ROP. ROP screening started in Tanzania for the first time in Muhimbili National Hospital in Dar es Salaam in late 2019. This study determines the prevalence and factors associated with ROP in Muhimbili hospital from June 2020 to February 2021.
methodsA prospective cohort study was conducted among 193 preterm newborns with ≤34 weeks gestational age and ≤2000 g birth weight. ROP screening was performed using an indirect ophthalmoscope and 20D Volk lens on dilated fundus. Prevalence was determined as the proportion of babies with ROP. Cox regression model was used to assess the contribution of risk factors to the occurrence of ROP.
resultsThe prevalence of ROP was 29% (56/193), and of type 1 ROP was 8.8%. Majority had zone two (73.2%) and 41.1% had stage two disease. Aggressive ROP constituted 8.9%. Significant factors for ROP development were gestational age <32 weeks (hazard ratio 6.8, p value 0.00), birth weight <1500 g (hazard ratio 2.1, p value 0.02), Apgar score <7 (hazard ratio 1.9, p value 0.03), RDS (hazard ratio 3.3, p value 0.01) and oxygen supplementation for >1 week (hazard ratio 0.74, p value 0.03). Surfactant use had a protective effect (hazard ratio 0.2, p value 0.03).
conclusionPrevalence of ROP is fairly high in our setting. Screening is essential to prevent visual morbidity and blindness resulting from ROP in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.